RxDoctor Payments Data

Mathew Sapp, MD

Retina Specialist · Birmingham, ALNPI 1720023153

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Alcon at 43.1% of the total. That places this record below the midpoint for retina specialist clinicians in AL, where the typical reported total is $919.

$393in general payments, 2019–2025

Across 9 payments — averaging $43.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$169
  • Regeneron Healthcare Solutions, Inc.$122
  • AbbVie$86
  • Alimera Sciences, Inc.$16

What the payments were for

  • Food & beverage$393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$393 in reported general payments places this provider in the 20th percentile of 21 retina specialist providers in Alabama.

See all retina specialist providers in Alabama

Medicare billing

Part B allowed, 2024
$2,229,177
Medicare patients
1,054
Services billed
14,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate288$17,094
CombiganBrimonidine Tartrate/Timolol19$9,497
Ketorolac Tromethamine145$4,612
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$4,246
Brimonidine Tartrate59$2,487
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat113$1,821
Ofloxacin138$1,775
Difluprednate18$1,670
Bromfenac Sodium11$1,653
Latanoprost39$521
Dorzolamide Hcl28$475
Timolol Maleate29$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$86$9,49719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 21 retina specialist providers in Alabama.

Other retina specialist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →